Pubblicato in data September 22, 2017

The scientific committee of Innovabiomed is formed by Dr. Carlo A. Adami, innovator and pioneer of surgical techniques and by Professors Gino Gerosa and Giampaolo Tortora, respectively cardiac surgeon and oncologist of international fame.




Dr. Carlo A. Adami graduated in medicine and surgery on 26.11.1974 at the University of Rome with 110-110 cum laude. He then did his internship at the University Hospital of Rome and specialised in general surgery and cardio-angio-vascular surgery with the highest grades.

After being hired by the Hospital of Verona in 1975 in vascular surgery, he took on a permanent position in the same specialized branch in 1976, where he was assigned until December 30, 2007, working in the Department of Surgery at the University Hospital of Borgo Rome-Verona. He has been the holder of the Endovascular Surgery of the University Hospital in Verona from 1998 to 2007, managing a High Specialisation service, with managerial autonomy and direct responsibility for technical and financial human resources.

During his career he has always been involved in the healthcare organisation and modernisation of new technologies both in Italy and abroad. In 1977-1978, at the Texas Heart Institute in Houston, he developed the first innovative surgical technologies in the field of vascular and endovascular surgery. He has invented two minimally invasive surgical devices with international trademark (WO 01/00108 Al) and (IB 200 6000 250). He has created the first European reference centre for minimally invasive endovascular techniques in Verona, holding specialised and organizational courses for Italian and foreign doctors.

He has participated both as a speaker and moderator to numerous national and foreign conferences. He has personally organised 30 National Conventions and 10 International Conventions. He is the author of over 200 published scientific papers.

He has been a professor at the School of Specialisation in vascular surgery and in general surgery at the University of Verona as a contacted Professor and has prepared 20 doctors with specialised thesis.

He currently provides his expertise, as health advisor, at the Basilica di Stato di Santa Maria degli Angeli in Rome and at the Basilica dell’Odigitria under Monsignor Giuseppe M. Blanda. He also conducts scientific consultations both at national and international level without practising active surgery.


He was the founding partner of endovascular minimally invasive surgery contributing with the inventor of the technique (Professor J. C. Parodi) for creating and feasibility of the new techniques coordinating the European trials on aorta, carotid trunks and peripheral vascular branch.

He was responsible for the Centre-East Europe from 1997 to 2000 of the Italian Society of Surgery by organising stages in these countries aimed at modernizing and integrating their healthcare processes..

He has collaborated with the Veneto Region for the development of professional exchanges (paramedical doctors and students) with the Republic of Hungary and of Moldova. He has been a member of the National Board of Directors and responsible for the North East of the Italian Society of Technology Surgery with research, innovation and organisation assignments.





Born in Rovereto (TN) on 27.10.1957. Resident in Rovereto (TN) in Piazza San Marco 13.

Degree in Medicine and Surgery at the University of Verona (1983)
Specialisation in Cardiac Surgery at the University of Verona (1988)

Full Professor of Cardiac Surgery University of Padua since November 2015
Director of the Cardiac Surgery Department, Hospital of Padua, since February 2003
Director of Transplant Centre and Mechanical Circulatory Support since 2003
CORIS – Consortium for Health Research Scientific Director (since 2016)

National Heart Hospital, London, UK, November 1981; Harefield Hospital, UK, April 1986; National Heart Hospital, London, UK, January 1988-January 1989; University Hospital, London, Ontario, Canada, 1991; Texas Heart Institute, Houston, USA, 1995.

Alexis Carrel Award 1993; Lifetime Achievement in Heart Valve Disease (New York City 2012); Excellent Paduan Award (2011); Trento Person of the year Award (2014).

Editor in Chief “Journal Heart Valve Disease” (since 2012); The Annals of Thoracic Surgery; Cardiovascular Surgery; The European Journal Cardiothoracic Surgery; Tissue Engineering ; International Journal of Artificial Organs; The Italian Heart Journal; European Heart Journal; Referee of MURST (Italian Ministery of University and Research) for national relevant projects.

Italian Cardiac Surgery Society Vice President (since 2016); President Society for Heart and Valve Disease (2011-2012); Member of the “European Heart Valve Standards Working Group” (1997); President of the “Ross Surgical Society” (from 1998 to 2000); Chairman “Working Group on Tissue Engineering Society for Heart Valve Disease”(from 1999 to 2001); “Postgraduate Committee EACTS” (from 2000 to 2004); “New Technology Resource Group EACTS”; Co-Director “Heart Failure Course” EACTS Academy (since 2010); Member of the Board of Directors of the Italian Society of Cardiac Surgery.

Founding Member of the Society for Heart Valve Disease;Italian Cardiac Surgery Society; European Association for Cardio-Thoracic Surgery; American Association for Thoracic Surgery; International Society for Heart and Lung Transplantation; Society of Thoracic Surgeons.

He performed the first beating heart myocardial revascularisation surgery in Italy with Da Vinci robotic system. (First Italian robot enhanced coronary bypass Ital Heart J 2004 Jun; 5 (6) 475-8).

He performed the first Totally endoscopic robotic-guided pulmonary veins ablation with Da Vinci robotic system (Totally endoscopic robotic-guided pulmonary vein ablation: an alternative method for the treatment of atrial fibrillation Eur J Cardiothorac Surg 2004 Aug: 26 (2): 450-2).

He performed simultaneous coronary artery by-pass grafting and carotid endarterectomy in an awake Jehova’s witness patient without endotracheal intubation. Eur J Cardiothorac Surg 2005 Jan; 27 (1): 168-170).

He performed the first left ventricular assist implant with Berlin Heart Incor (2003).

He performed one of the world’s first stem cells transplant in a patient with post-ischemic myocardiopathy in 2002.

He lead the team that performed the first ABO-incompatible heart transplantation in Italy on paediatric patient (2006) (ABO-incompatible heart transplantation: crossing the immunological barrier. J Cardiovasc Med (Hagerstown2008 Aug; 9 (8): 854-7).

He performed the first Cardiowest total artificial heart transplant in Italy (2007).

On September 2011 he successfully performed the heart transplant on the patient with the world’s longest survival with a total artificial heart (3 years and 8 months).

In 2015 he performed the world’s first aortic valve replacement surgery combined with a mitral valve valvuloplasty without using extracorporeal circulation and with beating heart through the left ventricular apex.

On April 2015 he implanted a 50 cc Cariowest total artificial heart, in a boy who already had a heart transplant, for the first time in the world.

On May 2016 he performed, for the first time in the world, in a patient affected with mitral insufficiency, the implantation of a mitral loop without using extracorporeal circulation and with beating heart through the left ventricular apex.

Under his guide the Cardiac Surgery Centre of Padua has become the first Centre in Italy for number of heart transplants and implantation of ventricular assistance systems (artificial hearts) in 2015.

The Regenerative Medicine Research Laboratory founded and directed by him has developed the technology to for human cardiac valve decellularisation ( homograft) to be used in paediatric patients and adults with congenital heart disease. This technology has been gifted to the Tissue Bank of Treviso which as of today is the only Tissue Bank in Europe other than Hannover to possess this technology.

He is the author of more than 300 scientific publications and co-author of 8 books on cardiac surgery. International patents: 2.



Current role:
– Full Medical Oncology Professor and Director of Medical Oncology Specialisation School at the Medicine and Surgery School – University of Verona.
– Oncology Department Director and Manager of the Oncological Centre at the Integrated University Hospital of Verona.

Studies and training:: Studies and training: He graduated in Medicine and Surgery in 1984, and then obtained his Specialisation in Oncology and PhD in Cellular and Molecular Pathology.

He has studied in the United States for 5 years at the National Cancer Institute, NIH, of Bethesda, and subsequently studying at several US and European institutions, including MD Anderson Cancer Center, University of Texas, Houston.

Research Areas and activity
A significant part of the research activity has been dedicated to the discovery and development of new molecular aimed medicinal products. He has significantly contributed in this field to the discovery and development of several medicinal products currently used in clinical practice in oncology. Another area of interest is the identification of molecular biomarkers able to predict the effectiveness or resistance to new medicinal products.

The results of the scientific activity are attested by approximately 200 works published on the most prestigious international scientific papers (including New England J Medicine and Nature) for an Impact Factor of over 1500 and an H Index of 67. For these studies he has received numerous national and international scientific awards (including the Guido Venosta Award of the Italian Cancer Research Foundation as the best Italian researcher delivered to the Quirinale by the President of the Italian Republic for his contributions to innovative cancer therapies).


Role in scientific Bodies and Organisations
He has a role in the board of directors and scientific committees of several institutions including:
– Educational Committee dell’European Society for Medical Oncology (ESMO), in which he has already been Chairman of the Working group for Translational Research and Personalized Medicine;
– Scientific e Steering Committee in the International Consortium for the Genome of Cancer (ICGC);
– French National Centre for Scientific Research (CNRS);
– Institute for Cancer Research and Cure of Candiolo, Turin.
– Italian Association for Cancer Research (AIRC).

He has already been President of the Oncotech clinical research Consortium and a member of the board of national and international scientific bodies and associations.